Document Detail

Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats.
MedLine Citation:
PMID:  8305170     Owner:  NLM     Status:  MEDLINE    
The effects of long-term oral administration of quinapril on the occurrence of stroke and on mortality were investigated in young salt-loaded stroke-prone spontaneously hypertensive rats (SHR-SPs) during the treatment period (8th-34th week of age) and up to 6 weeks thereafter. Simultaneously, blood pressure, saline intake, diuresis, and proteinuria were investigated at regular intervals, and cerebrovascular, renal, and cardiac lesions were assessed after death. Untreated SHR-SPs served as controls. Quinapril completely suppressed stroke and mortality, afforded only limited protection v blood pressure rise, and prevented any increase in saline intake, diuresis, and proteinuria both during and after the treatment period. Quinapril long-lastingly prevented vascular fibrinoid necrosis development at the cerebral, but also at the renal and cardiac levels. In the kidneys, vascular intimal and medial hyperplasia were strongly reduced, as were the glomerular and tubulo-interstitial lesions. At the cardiac level, intimal and medial hyperplasia were slightly reduced but infarction and fibrosis were hardly affected. As the renin-angiotensin system is highly stimulated in SHR-SPs and as angiotensin II (AII) is responsible for fibrinoid necrosis formation, vessel obstruction, and stroke in these animals, we conclude that the long-lasting protection afforded by quinapril v stroke and mortality in SHR-SPs both during and after the treatment period is mostly due to the drug-induced interruption of the renin-angiotensin system.(ABSTRACT TRUNCATED AT 250 WORDS)
E Vacher; P Fornes; V Domergue; C Richer; P Bruneval; J F Giudicelli
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  American journal of hypertension     Volume:  6     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1994-03-16     Completed Date:  1994-03-16     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  951-9     Citation Subset:  IM    
Département de Pharmacologie, Faculté de Médecine Paris-Sud, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / blood
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Blood Pressure / physiology
Body Height / physiology
Body Weight / physiology
Brain / pathology
Cerebrovascular Disorders / epidemiology*,  prevention & control*
Diuresis / physiology
Heart Rate / physiology
Hypertension / drug therapy*,  mortality,  physiopathology
Isoquinolines / pharmacology*
Kidney / drug effects,  pathology,  physiology
Myocardium / pathology
Proteinuria / physiopathology
Rats, Inbred SHR / physiology*
Risk Factors
Time Factors
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Isoquinolines; 0/Tetrahydroisoquinolines; 11128-99-7/Angiotensin II; 82586-55-8/quinapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of long-term administration of 1,25 (OH)2 vitamin D3 on blood pressure and resistance artery ...
Next Document:  Chronic pressure-natriuresis relationship in dogs with inherited essential hypertension.